An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Revance to Participate in the William Blair 42nd Annual Growth Stock Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9 in Chicago. CEO Mark Foley is set to present on June 6 at 2:00 p.m. CT. Interested parties can access the live audio webcast on the company’s website, with a replay available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic products, including the long-acting neuromodulator DaxibotulinumtoxinA for Injection, currently pursuing U.S. regulatory approval for use in glabellar lines and cervical dystonia.
Positive
None.
Negative
None.
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the William Blair 42nd Annual Growth Stock Conference, taking place June 6-9, in Chicago. Chief Executive Officer, Mark Foley, is scheduled to present on Monday, June 6, at 2:00 p.m. CT / 3:00 p.m. ET.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.
About Revance Therapeutics, Inc.
Revance is a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation, long-acting neuromodulator product, DaxibotulinumtoxinA for Injection. Revance has successfully completed Phase 3 clinical programs for DaxibotulinumtoxinA for Injection in glabellar (frown) lines, for which the company is currently pursuing U.S. regulatory approval, and in cervical dystonia. Revance is also evaluating DaxibotulinumtoxinA for Injection in adult upper limb spasticity. Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which if approved, would be the first and only generic biosimilar to Botox® and Botox® Cosmetic. For more information or to join our team visit us at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.
